Skip to main content

Table 2 Comparison of the clinical variables of participants across the various clinician-derived ECOG-PS ratings

From: Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer

Clinical and QoL Variables

ECOG 1 (n = 51)

ECOG 2 (n = 125)

ECOG 3 (n = 47)

Test of Significance

Age (yrs)

70.57 ± 6.08

70.90 ± 7.85

70.40 ± 6.63

F = 0.096; p = 0.91

BMI (kg/m2)

24.14 ± 2.68

24.14 ± 3.78

24.01 ± 3.23

F = 0.028; p = 0.97

tPSA (ng/ml)

75.06 ± 48.86

91.02 ± 74.83

110.99 ± 54.87

F = 3.657; p = 0.027

ISUP 1 (n = 24)

9 (4.0%)

11 (4.9%)

4 (1.8%)

Χ2 = 16.47; p = 0.036

ISUP 2 (n = 10)

3 (1.3%)

6 (2.7%)

1 (0.4%)

ISUP 3 (n = 34)

13 (5.8%)

18 (8.1%)

3 (1.3%)

ISUP 4 (n = 55)

13(5.8%)

31 (13.9%)

11 (4.9%)

ISUP 5 (n = 100)

13 (5.8%)

59 (26.5%)

28 (12.6%)

PWB Mean Domain Score

19.06 ± 4.39

15.99 ± 4.15

13.23 ± 4.38

F = 23.08; p < 0.001

SFWB Mean Domain Score

15.21 ± 4.76

15.31 ± 5.21

16.69 ± 4.76

F = 1.47; p = 0.232

EWB Mean Domain Score

17.00 ± 3.71

16.53 ± 3.57

15.70 ± 3.91

F = 1.57; p = 0.210

FWB Mean Domain Score

12.31 ± 5.07

9.97 ± 5.03

9.09 ± 4.61

F = 5.90; p = 0.003

PCS Mean Score

23.90 ± 6.87

22.10 ± 6.64

19.91 ± 7.22

F = 4.206; p = 0.016

Mean FACT-P Score

87.66 ± 17.08

79.94 ± 17.49

74.56 ± 16.04

F = 7.360; p = 0.002

Mean HUI

0.709 ± 0.172

0.542 ± 0.248

0.207 ± 0.419

F = 41.490; p < 0.001

Mean VAS

66.65 ± 8.54

60.08 ± 8.01

51.53 ± 10.67

F = 36.672; p < 0.001

  1. [ECOG: eastern cooperative oncology group; BMI: body mass index; tPSA: total serum prostate specific antigen; ISUP: international society of urological pathology; PWB: physical well-being; SFWB: social/family well-being; EWB: emotional well-being; FWB: functional well-being; PCS: prostate cancer subscale; FACT-P: functional assessment for cancer therapy – prostate; HUI: EuroQol health utility index; VAS: EuroQol visual analogue scale]